The Globe and Mail reports in its Wednesday, Jan. 12, edition that Canaccord Genuity analyst Matt Bottomley continues to rate Tilray "hold." The Globe's David Leeder writes that Mr. Bottomley cut his share target to $9 (U.S.) from $12 (U.S.). He made the target change following Monday's second quarter earnings release. Mr. Bottomley says in note: "Tilray reported FQ2/22 financial results (ended November, 2021) that came in below top-line consensus expectations in what continues to be a highly saturated industry landscape. Although the quarter fell short of our revenue forecasts, we note that Tilray was still able to make incremental progress in its adjusted EBITDA profile as it crystalizes synergies following Aphria's reverse acquisition of the company." The Globe reported on June 14 that CIBC World Markets analyst John Zamparo saw limited upside at Tilray, which he rated "neutral." The shares were then worth $19.16 (U.S.). The Globe reported on July 29 that Mr. Zamparo continued to rate the shares "neutral." They were then worth about $10 (U.S.). The Globe reported on Oct. 9 that Mr. Bottomley had reaffirmed his "market perform" recommendation for Tilray. The shares could then be had for about $11 (U.S.).
© 2022 Canjex Publishing Ltd. All rights reserved.